A meta‐analysis demonstrated the clinically significant correlation between CXCR4 overexpression and poor prognosis of breast cancer patients as well as patients with many other malignancies, including hematological, colorectal, esophageal, head and neck, lung, and gynecologic malignancies (Zhao et al, 2015). Here, CXCR4 is linked to breast cancer.